Provided by Tiger Trade Technology Pte. Ltd.

Clearmind Medicine, Inc.

1.01
-0.0500-4.72%
Volume:57.25K
Turnover:58.14K
Market Cap:1.50M
PE:-0.01
High:1.05
Open:1.00
Low:1.00
Close:1.06
52wk High:524.00
52wk Low:0.9199
Shares:1.49M
Float Shares:1.48M
Volume Ratio:0.03
T/O Rate:3.88%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-175.9200
EPS(LYR):-303.4772
ROE:-114.61%
ROA:-51.35%
PB:0.13
PE(LYR):0.00

Loading ...

Clearmind Signs LOI to Buy 51% Stake in EV Wireless Charging Firm for $2.5 Million

Reuters
·
Aug 03

Clearmind Medicine Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems Company

THOMSON REUTERS
·
Aug 03

Clearmind Medicine - to Extend $1.50 Mln Loan at 4% Interest, Repayable in Two Years

THOMSON REUTERS
·
Aug 03

Clearmind Medicine - Deal Valued at $2.50 Mln for 51% Majority Stake

THOMSON REUTERS
·
Aug 03

Psychedelic: Clearmind reports safety findings for CMND-100

TIPRANKS
·
Jul 30

Clearmind Medicine announces safety results from Part A of CMND-100 tral

TIPRANKS
·
Jul 30

Clearmind Reports Positive Safety, Tolerability in Cmnd-100 Phase I/II Trial Part a Dose Escalation

Reuters
·
Jul 30

Clearmind Medicine - Study Achieves Primary Endpoint of Safety and Tolerability for Cmnd-100

THOMSON REUTERS
·
Jul 30

Clearmind Medicine - no Serious Adverse Events Observed in Part a of Cmnd-100 Trial

THOMSON REUTERS
·
Jul 30

Clearmind Announces Positive Safety Findings for Cmnd 100, Demonstrating Consistent Tolerability Throughout Full Dose Escalation in Part a of Its FDA-Regulated Clinical Trial

THOMSON REUTERS
·
Jul 30

Clearmind Medicine - All 24 Participants Successfully Complete Treatment in Part a of Cmnd-100 Trial

THOMSON REUTERS
·
Jul 30

Clearmind Medicine completes Part A of CMND-100 trial

TIPRANKS
·
Jul 28

Clearmind Medicine Successfully Completes Part a of Its FDA Regulated Phase I/Ii Trial

Reuters
·
Jul 28

Clearmind Completes Part a Dosing in Phase I/II Cmnd-100 Trial for Alcohol Use Disorder

Reuters
·
Jul 28

Clearmind Targets Hong Kong Patent Protection to Support PTSD Drug Development Push

Reuters
·
Jul 20

Clearmind Medicine - Files Hong Kong Patent Application for Psychedelic Compounds Targeting Ptsd

THOMSON REUTERS
·
Jul 20

Clearmind reports positive retention results for intranasal formulation of MEAI

TIPRANKS
·
Jul 16

Clearmind Medicine Releases Update on Intranasal MEAI Formulation Retention Study

Reuters
·
Jul 16

Clearmind Medicine - Results Validate Clearmind Nasal Drug-delivery Platform for Meai

THOMSON REUTERS
·
Jul 16

Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of Its Psychedelic-based Neuroplastogen Meai

THOMSON REUTERS
·
Jul 16